GC Biopharma Corp.(KR:006280)
₩132,000.00+1200.00 (+0.92%)
KR:006280
GC Biopharma Corp. financials statements
₩132,000.00
At close:+1200.00 (+0.92%)
Want to see KR:006280 full AI Analyst Report?
GC Biopharma Corp. (006280) Ratios
GC Biopharma Corp. Ratios
KR:006280's free cash flow for Q2 2026 was ₩5.55B. For the 2026 fiscal year, KR:006280's free cash flow was decreased by ₩-14.22B and operating cash flow was ₩19.78B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.20 | 1.56 | 1.20 | 1.81 | 1.98 |
| Quick Ratio | 0.42 | 0.59 | 0.60 | 0.99 | 1.16 |
| Cash Ratio | 0.04 | 0.03 | 0.06 | 0.19 | 0.34 |
| Solvency Ratio | 0.05 | 0.04 | 0.04 | 0.14 | 0.19 |
| Operating Cash Flow Ratio | 0.09 | -0.07 | -0.01 | 0.22 | 0.23 |
| Short-Term Operating Cash Flow Coverage | 0.16 | -0.14 | -0.01 | 0.64 | 0.56 |
| Net Current Asset Value | ₩ -206.43B | ₩ -61.03B | ₩ -64.30B | ₩ 21.54B | ₩ 133.23B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.33 | 0.30 | 0.27 | 0.23 | 0.25 |
| Debt-to-Equity Ratio | 0.81 | 0.66 | 0.56 | 0.43 | 0.48 |
| Debt-to-Capital Ratio | 0.45 | 0.40 | 0.36 | 0.30 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.17 | 0.21 | 0.06 | 0.17 | 0.18 |
| Financial Leverage Ratio | 2.44 | 2.19 | 2.03 | 1.90 | 1.93 |
| Debt Service Coverage Ratio | 0.24 | 0.19 | 0.21 | 0.83 | 0.52 |
| Interest Coverage Ratio | 1.35 | 0.79 | 1.21 | 4.42 | 5.89 |
| Debt to Market Cap | 0.48 | 0.35 | 0.42 | 0.32 | 0.20 |
| Interest Debt Per Share | 90453.93 | 76104.57 | 65934.05 | 52040.30 | 54242.94 |
| Net Debt to EBITDA | 6.00 | 10.02 | 6.14 | 2.51 | 2.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 26.92% | 28.69% | 29.79% | 34.00% | 33.85% |
| EBIT Margin | 3.41% | -0.04% | 2.08% | 7.14% | 6.73% |
| EBITDA Margin | 7.81% | 4.78% | 6.75% | 10.93% | 10.34% |
| Operating Profit Margin | 3.41% | 1.91% | 2.12% | 4.75% | 4.79% |
| Pretax Profit Margin | -1.77% | -2.45% | -1.67% | 5.01% | 11.22% |
| Net Profit Margin | -0.23% | -1.56% | -1.64% | 3.82% | 8.01% |
| Continuous Operations Profit Margin | -1.49% | -2.54% | -1.22% | 4.06% | 8.91% |
| Net Income Per EBT | 13.23% | 63.93% | 98.15% | 76.35% | 71.40% |
| EBT Per EBIT | -52.10% | -128.04% | -78.80% | 105.49% | 234.26% |
| Return on Assets (ROA) | -0.16% | -0.96% | -1.01% | 2.59% | 5.00% |
| Return on Equity (ROE) | -0.38% | -2.10% | -2.05% | 4.93% | 9.67% |
| Return on Capital Employed (ROCE) | 3.71% | 1.63% | 1.94% | 4.09% | 3.86% |
| Return on Invested Capital (ROIC) | 2.33% | 1.36% | 1.09% | 3.01% | 2.73% |
| Return on Tangible Assets | -0.18% | -1.08% | -1.10% | 2.96% | 5.64% |
| Earnings Yield | -0.26% | -1.28% | -1.85% | 4.52% | 4.95% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.86 | 4.12 | 3.72 | 4.13 | 3.62 |
| Payables Turnover | 8.21 | 7.64 | 7.94 | 9.31 | 8.51 |
| Inventory Turnover | 1.63 | 1.60 | 2.21 | 2.55 | 2.24 |
| Fixed Asset Turnover | 2.07 | 1.83 | 1.71 | 1.84 | 1.71 |
| Asset Turnover | 0.67 | 0.61 | 0.62 | 0.68 | 0.62 |
| Working Capital Turnover Ratio | 6.06 | 5.58 | 5.33 | 3.48 | 2.83 |
| Cash Conversion Cycle | 254.26 | 268.32 | 217.08 | 192.18 | 221.21 |
| Days of Sales Outstanding | 75.10 | 88.62 | 98.05 | 88.41 | 100.85 |
| Days of Inventory Outstanding | 223.62 | 227.47 | 165.00 | 142.96 | 163.25 |
| Days of Payables Outstanding | 44.46 | 47.78 | 45.97 | 39.19 | 42.89 |
| Operating Cycle | 298.72 | 316.10 | 263.05 | 231.37 | 264.11 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 8714.10 | -4684.14 | -479.52 | 10440.23 | 11038.20 |
| Free Cash Flow Per Share | 2374.34 | -8398.43 | -11518.82 | 2143.53 | 213.81 |
| Dividend Paid and CapEx Coverage Ratio | 1.09 | -0.86 | -0.04 | 1.00 | 0.89 |
| Capital Expenditure Coverage Ratio | 1.37 | -1.26 | -0.04 | 1.26 | 1.02 |
| Operating Cash Flow Coverage Ratio | 0.10 | -0.06 | -0.01 | 0.21 | 0.21 |
| Operating Cash Flow to Sales Ratio | 0.05 | -0.03 | -0.00 | 0.07 | 0.08 |
| Free Cash Flow Yield | 1.49% | -4.68% | -9.16% | 1.69% | 0.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -388.27 | -77.95 | -53.91 | 22.14 | 20.19 |
| Price-to-Sales (P/S) Ratio | 0.91 | 1.22 | 0.88 | 0.85 | 1.62 |
| Price-to-Book (P/B) Ratio | 1.49 | 1.64 | 1.10 | 1.09 | 1.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 66.97 | -21.37 | -10.92 | 59.25 | 1019.58 |
| Price-to-Operating Cash Flow Ratio | 18.25 | -38.32 | -262.34 | 12.16 | 19.75 |
| Price-to-Earnings Growth (PEG) Ratio | 4.72 | 59.06 | 0.38 | -0.47 | 0.39 |
| Enterprise Value Multiple | 17.67 | 35.52 | 19.22 | 10.26 | 18.29 |
| Enterprise Value | 2.75T | 2.85T | 2.11T | 1.92T | 2.91T |
| EV to EBITDA | 17.67 | 35.52 | 19.22 | 10.26 | 18.29 |
| EV to Sales | 1.38 | 1.70 | 1.30 | 1.12 | 1.89 |
| EV to Free Cash Flow | 101.38 | -29.78 | -16.05 | 78.47 | 1191.90 |
| EV to Operating Cash Flow | 27.62 | -53.39 | -385.56 | 16.11 | 23.09 |
| Tangible Book Value Per Share | 92603.81 | 102832.77 | 114888.48 | 109969.22 | 107101.65 |
| Shareholders’ Equity Per Share | 106665.25 | 109755.97 | 113925.90 | 116369.27 | 111694.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.16 | -0.04 | 0.27 | 0.19 | 0.21 |
| Revenue Per Share | 174459.36 | 147191.09 | 142525.52 | 149944.16 | 134743.34 |
| Net Income Per Share | -409.48 | -2302.66 | -2333.46 | 5734.96 | 10795.74 |
| Tax Burden | 0.13 | 0.64 | 0.98 | 0.76 | 0.71 |
| Interest Burden | -0.52 | 61.31 | -0.80 | 0.70 | 1.67 |
| Research & Development to Revenue | 0.08 | 0.10 | 0.11 | 0.11 | 0.09 |
| SG&A to Revenue | 0.08 | 0.08 | 0.08 | 0.10 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -21.28 | 1.25 | 0.21 | 1.72 | 0.92 |
Currency in KRW

